|
|
 |
|
Viewing report
|
|
|
|
Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry
GlobalData, Aug 2011, Pages: 7
Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry
Summary
GlobalData’s viewpoint, “Increasing Collaboration Between Big Pharma and Academia to Counter R&D, Patent and Approval Issues in the Industry” is a featured article highlighting the importance of increasing collaboration between Big Pharma and Academia to Counter R&D and how it is developing as a new business model has become an important issue
Scope
- This report will describe the strategic overview, history of deals, major resent failures nature of the collaboration agreements and reasons for the increasing trend towards collaboration of big pharma and academia
Reasons to buy
- Understand the limitations of these kind of collaborations with risk and benefits analysis.
- This report will enable companies to decide their strategy for pipeline development
|
|
|
|
